BioPorto A/S Sustainability Reports

BioPorto A/S is an in vitro diagnostics company focused on developing and commercializing biomarker-based tests. Its primary product line includes the NGAL Test used for the early risk assessment and diagnosis of acute kidney injury.

Sector: Professional & technical services

Country: Denmark

Exchange: Nasdaq Copenhagen

LEI: 5299004SWFL5JAN4W830

FIGI: BBG001SB4RF2

25 reports from 2015 to 2025

• BioPorto A/S 2025 Annual Report
• BioPorto A/S 2025 Corporate Governance Report
• BioPorto A/S 2025 Annual Report
• BioPorto A/S 2024 Annual Report
• BioPorto A/S 2024 Annual Report